What is Zacks Research's Estimate for JNJ FY2025 Earnings?

Key Points

• Analysts at Zacks Research have raised their FY2025 earnings per share (EPS) estimate for Johnson & Johnson from $10.59 to $10.84, exceeding the current consensus estimate of $10.58.
• Johnson & Johnson reported Q2 earnings of $2.77 per share, surpassing estimates, and revenues of $23.74 billion, which exceeded analyst expectations of $22.85 billion.
• The stock currently holds a consensus rating of "Moderate Buy" with a target price average of $174.50 from various analysts.

Johnson & Johnson (NYSE:JNJ - Free Report) - Research analysts at Zacks Research boosted their FY2025 earnings estimates for Johnson & Johnson in a research report issued to clients and investors on Tuesday, July 29th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $10.84 for the year, up from their prior forecast of $10.59. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q1 2026 earnings at $2.63 EPS, Q1 2027 earnings at $2.86 EPS, Q2 2027 earnings at $3.07 EPS and FY2027 earnings at $12.07 EPS.

A number of other equities analysts have also commented on JNJ. Bank of America lifted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Trading Down 1.5%

Shares of NYSE:JNJ traded down $2.50 during mid-day trading on Wednesday, reaching $164.76. 9,876,897 shares of the company's stock were exchanged, compared to its average volume of 8,007,298. The firm has a market capitalization of $396.81 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 2.13 and a beta of 0.41. The business's fifty day moving average price is $157.18 and its 200-day moving average price is $156.44. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.82 earnings per share.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Conquis Financial LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $33,000. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson during the 4th quarter valued at $36,000. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Finally, Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at $47,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.